Pacific Biosciences of California Debt to Equity Ratio:
0.12 for Dec. 31, 2012Pacific Biosciences of California Historical Debt to Equity Ratio Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 0.12 |
| Dec. 31, 2012 | 0.00 |
| Sept. 30, 2012 | 0.022 |
| June 30, 2012 | 0.0193 |
| March 31, 2012 | 0.0172 |
| Dec. 31, 2011 | 0.00 |
| Sept. 30, 2011 | 0.014 |
| June 30, 2011 | 0.0128 |
| March 31, 2011 | 0.0121 |
| Dec. 31, 2010 | 0.0109 |
| Sept. 30, 2010 | |
| June 30, 2010 | 0.0005 |
About Debt to Equity Ratio
Leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. A low debt to equity ratio indicates lower risk, because debt holders have less claims on the company's assets. A debt to equity ratio of 5 means that debt holders have a 5 times more claim on assets than equity holders.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
PACB Debt to Equity Ratio Benchmarks
| Companies | |
|---|---|
| NPS Pharmaceuticals | |
| Lexicon Pharmaceuticals | 0.0879 |
| MannKind Corporation |
PACB Debt to Equity Ratio Rankings
| Overall |
76th percentile 1875 of 8002 |
| Sector |
53rd percentile 300 of 650 in Healthcare |
| Industry |
45th percentile 128 of 237 in Biotechnology |
PACB Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Dec 2011 |
| Maximum | 0.1200 | Mar 2013 |
| Average | 0.0208 |
